Efficacy of Linvoseltamab in Prespecified High Risk Subgroups of Patients with Relapsed/Refractory Multiple Myeloma: Results from LINKER-MM1

被引：0

作者：

Suvannasankha, Attaya ^{[1
,2
]}

Lee, Hans ^{[3
]}

Bumma, Naresh ^{[4
]}

Dhodapkar, Madhav V. ^{[5
]}

Richter, Joshua ^{[6
]}

Hoffman, James E. ^{[7
]}

Shah, Mansi ^{[8
]}

Lentzsch, Suzanne ^{[9
]}

Zonder, Jeffrey ^{[10
]}

Baz, Rachid ^{[11
]}

Maly, Joseph J. ^{[12
]}

Namburi, Swathi ^{[13
]}

Wu, Ka Lung ^{[14
]}

Pianko, Matthew ^{[15
]}

Silbermann, Rebecca ^{[16
]}

Min, Chang-Ki ^{[17
]}

Vekemans, Marie-Christiane ^{[18
]}

Munder, Markus ^{[19
]}

Martinez Lopez, Joaquin ^{[20
]}

DeVeaux, Michelle ^{[21
]}

Chokshi, Dhruti ^{[21
]}

Boyapati, Anita ^{[21
]}

Kroog, Glenn S. ^{[21
]}

Houvras, Yariv ^{[21
]}

Jagannath, Sundar ^{[22
]}

机构：

[1] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA

[2] Roudebush VAMC, Indianapolis, IN USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[5] Emory Univ, Sch Med, Atlanta, GA USA

[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[7] Univ Miami Hlth Syst, Miami, FL 33125 USA

[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Karmanos Canc Inst, Detroit, MI 48201 USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] Norton Canc Inst, Louisville, KY USA

[13] Swedish Canc Inst, Seattle, WA USA

[14] ZNA Cadix, Antwerp, Belgium

[15] Univ Michigan Hlth, Rogel Canc Ctr, Ann Arbor, MI USA

[16] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[17] Catholic Univ Korea, St Marys Hosp, Seoul, South Korea

[18] Univ Catholic Louvain UCLouvain, Clin Univ St Luc, Dept Hematol, Brussels, Belgium

[19] Univ Med Ctr Mainz, Dept Internal Med 3, Mainz, Germany

[20] Univ Complutense, Hosp 12 Octubre, CNIO, Sch Med ,i 12, Madrid, Spain

[21] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[22] Mt Sinai Med Ctr, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-084

引用

页码：S90 / S91

页数：2

共 50 条

[41] BORTEZOMIB RETREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RESULTS IN A COHORT OF 52 PATIENTS
Canovas, A.
Alonso, J. J.
Barreiro, B.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 617 - 618
[42] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
Richardson, Paul
Jagannath, Sundaf
Raje, Noopur
Jakubowiak, Andrzej
Lonial, Sagar
Ghobrial, Irene
Schlossman, Robert
Mazumder, Amitabha
Munshi, Nikhil
Colson, Kathleen
McKenney, Mary
Farrell, Melissa
Lunde, Laura
Giove, Lawrence
Kaster, Sarah
Mitsiades, Constantine
Hideshima, Teru
Knight, Robert
Esseltine, Dixie-Lee
Anderson, Kenneth
BLOOD, 2007, 110 (11) : 797A - 797A
[43] Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
Richardson, Paul G.
Chanan-Khan, Asher A.
Lonial, Sagar
Krishnan, Amrita Y.
Carroll, Michael P.
Alsina, Melissa
Albitar, Maher
Berman, David
Messina, Marianne
Anderson, Kenneth C.
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 729 - 740
[44] Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
Xin Miao
Liviawati S. Wu
Shun Xin Wang Lin
Yan Xu
Yang Chen
Yuki Iwaki
Rachel Kobos
Tara Stephenson
Kristy Kemmerer
Clarissa M. Uhlar
Arnob Banerjee
Jenna D. Goldberg
Danielle Trancucci
Amit Apte
Raluca Verona
Lixia Pei
Rachit Desai
Kathleen Hickey
Yaming Su
Daniele Ouellet
Mahesh N. Samtani
Yue Guo
Alfred L. Garfall
Amrita Krishnan
Saad Z. Usmani
Honghui Zhou
Suzette Girgis
Targeted Oncology, 2023, 18 : 667 - 684
[45] A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma
Vogl, Dan T.
Nefedova, Yulia
Wileyto, E. Paul
Sembhi, Harjeet
Strakovsky, Inna
Nguyen, Chau
Taneja, Rimzim
Bondesson, Eva
Eriksson, Helena
Tuvesson, Helen
BLOOD, 2020, 136
[46] Treatment efficacy for relapsed/refractory multiple myeloma patients with gain/amplification of 1q21
Zhou, Xia
Wu, Hongying
Hao, Lumei
Wei, Liyan
Li, Xuemei
Yin, Junjing
Yu, Qianru
Xie, Zhanzhi
Zhong, Yuping
CHINESE MEDICAL JOURNAL, 2025, 138 (07) : 871 - 873
[47] Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM)
Maignan, Kathleen
Backenroth, Daniel
McQuarrie, Neil A.
Lipitz, Nicole G.
Williams, Erin R.
Carson, Kenneth R.
BLOOD, 2018, 132
[48] Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
Gasparetto, Cristina
Lipe, Brea
Tuchman, Sascha
Callander, Natalie Scott
Lentzsch, Suzanne
Baljevic, Muhamed
Rossi, Adriana C.
Bahlis, Nizar J.
White, Darell
Chen, Christine
Sutherland, Heather J.
Kotb, Rami
LeBlanc, Richard
Sebag, Michael
Venner, Christopher P.
Bensinger, William
Sheehan, Heidi
Ju, Yawen
Kai, Kazuharu
Schiller, Gary J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[49] A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).
Berenson, James R.
To, Jennifer
Spektor, Tanya M.
Martinez, Daisy
Sanchez, Armando Jose
Ghermezi, Matthew
Turner, Carley
Swift, Regina A.
Eades, Benjamin M.
Schwartz, Gary
Eshaghian, Shahrooz
Stampleman, Laura
Moss, Robert A.
Nassir, Youram
Patel, Ravindranath
Bessudo, Alberto
Lim, Stephen
Vescio, Robert A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[50] Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
Dimopoulos, M. A.
Sonneveld, P.
Siegel, D.
Palumbo, A.
San-Miguel, J.
ANNALS OF ONCOLOGY, 2015, 26 (11) : 2247 - 2256

← 1 2 3 4 5 →